caa a22 4500 445336471 CHVBK 20180317142757.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1245/s10434-011-1613-7 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1613-7 Lens Culinaris Agglutinin-Reactive Fraction of Alpha-Fetoprotein as a Marker of Prognosis and a Monitor of Recurrence of Hepatocellular Carcinoma After Curative Liver Resection [Elektronische Daten] [Xiao-Feng Zhang, Eric Lai, Xiao-Yan Kang, Hai-Hua Qian, Yan-Ming Zhou, Le-Hua Shi, Feng Shen, Ye-Fa Yang, Yu Zhang, Wan Lau, Meng-Chao Wu, Zheng-Feng Yin] Background: The aim of this study was to determine the role of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) as a prognostic marker and a monitor marker of recurrence after curative resection of hepatocellular carcinoma (HCC). Methods: From December 2002 to May 2004, 395 consecutive patients with HCC who underwent curative partial hepatectomy were included in the study. The tumor characteristics and clinical outcomes of patients with positive preoperative and postoperative AFP-L3 were compared with those with negative results. Results: A high ratio of AFP-L3 to total AFP was an indicator of pathologic aggressiveness. Patients with positive preoperative AFP-L3 had significantly earlier recurrence (median time to recurrence 22.0±2.4months vs 45.0±6.9months, P<.001) when compared with those with negative preoperative results. Significantly more patients with continuously positive or negative-turn-positive AFP-L3 results after surgery developed recurrence, particularly distant metastases, when compared with patients with continuously negative AFP-L3 results. The overall and disease-free survivals were significantly shorter in the positive than the negative preoperative AFP-L3 group. The overall and disease-free survivals were significantly shorter in the continuously positive and the negative-turn-positive than the continuously negative postoperative AFP-L3 group. Conclusion: Positive preoperative AFP-L3 and continuously positive or negative-turn-positive AFP-L3 results after surgery predicted a more aggressive tumor behavior, higher tumor recurrence, and poorer clinical outcomes. HCC patients with an increased proportion of AFP-L3 to total AFP should be more aggressively treated and closely followed-up. Society of Surgical Oncology, 2011 Zhang Xiao-Feng Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Lai Eric Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Kang Xiao-Yan Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Qian Hai-Hua Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Zhou Yan-Ming Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Shi Le-Hua Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Shen Feng Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Yang Ye-Fa Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Zhang Yu Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Lau Wan Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Wu Meng-Chao Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Yin Zheng-Feng Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2218-2223 1068-9265 18:8<2218 2011 18 10434 https://doi.org/10.1245/s10434-011-1613-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1613-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zhang Xiao-Feng Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Lai Eric Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Kang Xiao-Yan Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Qian Hai-Hua Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Zhou Yan-Ming Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Shi Le-Hua Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Shen Feng Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Yang Ye-Fa Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Zhang Yu Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Lau Wan Department of Comprehensive Treatment, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Wu Meng-Chao Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Yin Zheng-Feng Molecular Oncology Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/8(2011-08-01), 2218-2223 1068-9265 18:8<2218 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer